Augurex’s Spinestat diagnostic test earned the FDA’s breakthrough device designation.
Spinestate is a 14-3-3eta autoantibody multiplex immunoassay test for diagnosing axial spondyloarthritis, according to an Oct. 28 news release. It’s designed to address an unmet need in the early and accurate differentiation of axSpA in patients with chronic back pain.
With breakthrough designation, Augurex will get additional collaboration and support from the FDA during the regulatory approval process.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
